secwatch / observer
8-K filed December 16, 2025, 6:59 PM ET ticker LEXX CIK 0001348362
other confidence high sentiment neutral materiality 0.55

Lexaria raises $3.5M in registered direct offering with warrants

Lexaria Bioscience Corp.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Lexaria Bioscience Corp. issued 93,156 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC or its designees for exercise price of $1.6438 per share.

Security
warrant
Shares
93,156 shares of Common Stock
Purchaser
H.C. Wainwright & Co., LLC or its designees
Consideration
exercise price of $1.6438 per share
Exact text from the filing
number of Shares issued and sold on the Closing Date. The Placement Agent Warrants expire five years from the commencement of sales of the Offering and have an exercise price of $1.6438 per share of Common Stock armel, LLP, securities counsel to the Company, delivered an opinion as to the validity of the Shares, a copy of which is filed as Exhibit 5.1 to this
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Lexaria Bioscience Corp. issued 2,661,600 shares of common stock to certain institutional investors for $1.315 per share.

Security
common stock
Shares
2,661,600 shares
Purchaser
certain institutional investors
Consideration
$1.315 per share
Exact text from the filing
the Company issued and sold to the investors (i) in a registered direct offering, 2,661,600 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $1.315 per share
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Lexaria Bioscience Corp. issued up to 2,661,600 shares of Common Stock of warrant to certain institutional investors for exercise price of $1.19 per share.

Security
warrant
Shares
up to 2,661,600 shares of Common Stock
Purchaser
certain institutional investors
Consideration
exercise price of $1.19 per share
Exact text from the filing
in a concurrent private placement, 2,661,600 common stock purchase warrants (the “Private Placement Warrants”), exercisable for an aggregate of up to 2,661,600 shares of Common Stock, at an exercise price of $1.19 per share of Common Stock
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Lexaria Bioscience Corp. entered into Purchase Agreement with certain institutional investors valued at approximately $3.5 million (effective 2025-12-14).

Action
entry
Agreement
equity purchase
Counterparty
certain institutional investors
Value
approximately $3.5 million
Effective
2025-12-14
Exact text from the filing
On December 14, 2025, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold to the investors (i) in a registered direct offering, 2,661,600 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $1.315 per share, and (ii) in a concurrent private placement, 2,661,600 common stock purchase warrants (the “Private Placement Warrants”), exercisable for an aggregate of up to 2,661,600 shares of Common Stock, at an exercise price of $1.19 per share of Common Stock.
View on SEC.gov

Browse all equity issuances →

Lexaria Bioscience Corp. filing history →

Source: SEC EDGAR
accession 0001640334-25-002348
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.